Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of iptacopan for C3 glomerulopathy or idiopathic immune complex-mediated membranoproliferative glomerulonephritis
CTR20230591Phase 3Active
- Sponsor
- Novartis
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in Complement 3 glomerulopathy (C3G), Primary immune complex membranoproliferative glomerulonephritis (MPGN), sponsored by Novartis. Started Jul 2023; status: active.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on CTR20230591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230591.